Combined treatment of CB-839 (GLS1 inhibitor) and metformin could synergistically impair proliferation of ESCC cells, providing promising therapeutic strategy for anti-ESCC treatment. The gene discussed is GLS; the disease is esophageal squamous cell carcinoma.